PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Vedolizumab Is Associated With Longer Drug Sustainability Compared to Infliximab in Moderate-To-Severe Ulcerative Colitis: Long Term Real-World Cohort Data
Konikoff, T.; Yanai, H.; Libchik, D.; Avni-Biron, I.; Snir, Y.; Banai, H.; Broytman, Y.; Dotan, I.; Ollech, J.E. Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data. J. Clin. Med.2023, 12, 4488.
Konikoff, T.; Yanai, H.; Libchik, D.; Avni-Biron, I.; Snir, Y.; Banai, H.; Broytman, Y.; Dotan, I.; Ollech, J.E. Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data. J. Clin. Med. 2023, 12, 4488.
Konikoff, T.; Yanai, H.; Libchik, D.; Avni-Biron, I.; Snir, Y.; Banai, H.; Broytman, Y.; Dotan, I.; Ollech, J.E. Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data. J. Clin. Med.2023, 12, 4488.
Konikoff, T.; Yanai, H.; Libchik, D.; Avni-Biron, I.; Snir, Y.; Banai, H.; Broytman, Y.; Dotan, I.; Ollech, J.E. Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data. J. Clin. Med. 2023, 12, 4488.
Abstract
Background & Aim: Drug sustainability (DS) is a surrogate marker for treatment efficacy. We aimed to compare the DS of two main biologics used to treat moderate-to-severe ulcerative colitis (UC), infliximab (IFX) and vedolizumab (VDZ), in a real-world setting. Methods: We conducted a retrospective cohort study at a tertiary medical center in Israel. We included patients treated between Dec 1st, 2017, and May 1st, 2021, who were followed for up to 300 weeks. DS was defined as corticosteroid, surgical, and hospitalization-free treatment. Results: 217 patients with UC were included. VDZ had a significantly longer median DS of 265.6 weeks compared to IFX's 106.5 weeks (p=0.001) in treatment-naïve patients, even when adjusting for disease severity (HR 0.55 95 CI 0.3-0.98, p=0.042). In treatment-experienced patients, DS was comparable between IFX and VDZ (p=0.593). Conclusion: VDZ showed significantly longer DS in treatment-naïve patients with UC compared to IFX, also when adjusted for disease severity. There was no difference in DS between VDZ and IFX in treatment-experienced patients and patients switching from one drug to another. VDZ may be a suitable first-line treatment for biologic-naïve patients with moderate-to-severe UC.
Keywords
Biologics in UC; drug efficacy in UC; drug survival in UC
Subject
Medicine and Pharmacology, Clinical Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
